Physician Insights

Treatment decisions are shaped by practicing specialists and the KOLs whose opinions carry weight in a specific therapeutic area. Spherix tracks both, across therapeutic areas where Spherix has built deep, continuous presence.

What that means in practice: you see what physicians and APPs report prescribing, what chart audits confirm, how new launches are landing in real-world practice, and how sentiment shifts as the competitive landscape changes. Not a snapshot – a trend line you can act on.

Spherix has been delivering physician research for over a decade, with sample sizes scaled to the market, not to a one-size-fits-all methodology.

Download the Publication Plan

Your guide to every Spherix publication scheduled for 2026, organized by therapeutic area, indication, and deliverable, spanning all eight therapeutic franchises and the Market Access practice across US, EU4+UK, and select global markets.

DOWNLOAD PLAN →

Physician Solutions

Spherix’s physician solutions are built on a foundation most research vendors cannot replicate: continuous primary data from a rigorously vetted physician community, interpreted by therapeutic area specialists who know your market – not generalists running a methodology.

That combination means the output is not a report you hand to someone else to interpret. It is a commercial answer, delivered with the context to act on it – whether you are tracking competitive dynamics, preparing for launch, benchmarking access, or building the market case for a pipeline asset.

Every output is reviewed and validated by our therapeutic area expert who understands the market, with AI accelerating how quickly that decade of physician trend data becomes an answer – surfacing shifts and segment differences that would otherwise take weeks to compile.

Regular trending of brand and class KPIs, drawn from the prescriber's point of view. Each wave blends core rotational content with event-driven and variable content, exploring brand use, intentions, promotional activity, disease awareness, controversy, and pipeline product perceptions. Sample size: ~100-200 providers per US quarterly wave; n=50-250 providers per EU4+UK, Canada, Brazil, China, and Japan semiannual wave.

Anonymized patient-level data gathered through collaboration with specialty providers, who provide details on clinical and non-clinical patient demographics along with rationale for treatment choices. Annual reports with global insights from US, EU4+UK, China, Japan and other select regions. Samples scale with disease prevalence at 100+ patients in extremely rare conditions, and up to 1,250+ patient charts in others.

Monthly KPI benchmarking of newly launched products for the first 18 months post-approval, augmented by a quarterly deep dive into promotional activity, barriers to uptake, patient types gravitating to the launch brand, and competitive analyses. Sample: ~75 providers per monthly/quarterly wave, with n=8 qualitative interviews per quarter.

Annual independent analysis of markets positioned for transformative growth in the next three to five years. Each report blends data from specialists and leading KOLs to capture market size, diagnosis and referral patterns, treatment approaches, adoption pathways, unmet needs, and pipeline evaluation. Sample: n=50-200 providers plus n=6-8 provider interviews and n=2-3 KOL interviews.

Delivers independent insights into the disease and treatment journey through the patient's perspective. Annual quantitative research with representative patient samples reveals unmet needs, treatment experiences, communication with providers, and opportunities to improve education, support, and patient outcomes.

Focused reasearch on emerging topics, disruptive market events, niche populations, and unique commercial questions. Special Topix is designed to address opportunities that require targeted insights outside the scope of ongoing syndicated research. Methodology and sample size are customized to each objective.

Inside the Spherix Physician Community

The Spherix physician community is a proprietary group of screened, practicing US specialty physicians and advanced practice providers (APPs) across all therapeutic franchises. What differentiates it is the rigor behind it; every participant is recruited and screened by Spherix, participation is weighted toward where patients are actually treated, respondent fatigue is actively managed to preserve trend consistency, and every clinician undergoes ongoing specialty verification and quality review.

The Spherix Difference

Primary research is only as valuable as the community and expertise behind it. Here is what distinguishes Spherix's Physician Community:

Cited by financial analysts, patient advocacy groups, and pharma steering committees – primary data with the credibility to stand on its own in rooms where sponsored research does not

A curated community of vetted, actively practicing specialty physicians, APPs, and KOLs across eight therapeutic franchises

Specialist-only samples – you hear from the physicians actually prescribing in your category, not a general panel

11+ years of continuous quarterly trending in most franchises – a depth of history that cannot be replicated by a new entrant or a one-off custom research project

An advisory relationship, not a transaction – Spherix specialists work alongside your team over time, with AI accelerating how quickly over a decade of trend data becomes an answer you can act on